BACKGROUND: Recent human trials with rapamycin-eluting stents have shown very low
restenosis rates. However, the high costs of these devices preclude their use in routine …

Rapamycin-coated stents are associated with low restenosis rates, but the ability of oral
rapamycin to prevent restenosis is unknown. From December 2001 through February 2002 …

Objective: To assess the role of oral rapamycin in the prevention of coronary restenosis in
patients undergoing coronary stenting. Methods: From December 2001 through February …

Objectives: The aim of this study was to establish safety and feasibility of oral Rapamycin at
two doses—2 mg and 5 mg—in achieving low rates of repeat target lesion revascularization …

Objectives: The purpose of this study was to assess the role of oral rapamycin in decreased
restenosis after bare metal stent implantation. Background: Small observational studies …

Objectives: To establish the efficacy of oral rapamycin at a dose of 2 mg for 1 month at
reducing the 6-month restenosis rate after the implantation of bare metal stents. Methods: A …

Objectives: The aim of this study was to assess the role of short oral administration of
rapamycin, without loading dose, in the reduction of restenosis rate after bare metal stent …

In response to physiological stimuli (eg, wound healing), normally quiescent smooth muscle
cells (SMCs) within the vessel wall can be activated to migrate and proliferate to produce …

The cellular action of rapamycin (sirolimus), a natural fermentation product produced by
Streptomyces hygroscopicus, is mediated by binding to the FK506 binding protein. By …

Background The results of clinical trials of rapamycin-eluting stents reduce restenosis have
been quite promising. The main purpose of this study was to characterize the in vivo …